Stratagene (NASDAQ:STGN)
Historical Stock Chart
From Jun 2019 to Jun 2024
Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and
marketer of specialized life science research and diagnostics products,
announced today that VWR International, Inc. will become a distributor
of Stratagene’s full line of research products
in Canada. The companies expect that customers will be able to access
Stratagene products through VWR beginning in October 2006.
Under the terms of the agreement, Stratagene and VWR will service
Canadian customers in an integrated manner. In addition to increasing
Stratagene’s presence in the Canadian market
with broader sales representation and customer relationships, VWR will
inventory Stratagene products in warehouses located in Edmonton and
Mississauga to provide Canadian customers with faster and more
economical delivery. Stratagene will continue to support Canadian
customers with direct sales representation and field applications
support personnel in Canada as well as provide technical support and
instrument service from its U.S. offices.
“Both of our companies possess strengths which
we want to leverage to provide the best life science research products
and support to our mutual Canadian customers,”
said Joseph A. Sorge, MD, President and CEO of Stratagene. “Stratagene
is recognized as a premier brand name in life sciences and is a leader
in many product areas, while VWR provides well-established, reputable
distribution and coverage of the Canadian market. Together, we believe
we offer Canadian customers unparalleled combination of value.”
"This agreement significantly enhances VWR's network of supplier
partnerships by extending Stratagene’s
industry-leading life science research products to our customers," said
Brian Kerslake, VWR Vice President of Life Science. "Our relationship
will continue to strengthen VWR's ability to provide our customers with
superior solutions and technology."
About Stratagene Corporation
Stratagene is a developer, manufacturer and marketer of specialized life
science research and diagnostic products. The Company's life science
research unit supports advances in science by inventing, manufacturing
and distributing products that simplify, accelerate and improve
research. These products are used throughout the academic, industrial
and government research sectors in fields spanning molecular biology,
genomics, proteomics, drug discovery and toxicology. The Company's
diagnostic unit develops and manufactures products for urinalysis as
well as high quality automated instrument and reagent systems that use
blood samples to test for more than 1,000 different allergies and
autoimmune disorders. In addition, by combining its expertise in
diagnostics and molecular biology, as well as its experience with FDA
regulatory procedures, the Company is pursuing opportunities to expand
its product portfolio to include molecular diagnostic kits and
instrumentation. More information is available at www.stratagene.com.
About VWR International, Inc.
VWR International is a leader in the global research laboratory industry
with worldwide sales in excess of $3.1 billion US dollars. VWR's
business is highly diversified across a spectrum of products and
services, customer groups and geography. The company offers more than
1,200,000 products, from more than 2,500 manufacturers, to over 250,000
customers throughout North America and Europe. VWR's primary customers
work in the pharmaceutical, life science, chemical, technology, food
processing and consumer product industries. Other important customers
include universities and research institutes; governmental agencies;
environmental testing organizations; and primary and secondary schools.
VWR International affiliates operate in 20 countries and employ
approximately 6,100 people. The company's mission is to deliver
excellence in the distribution of scientific supplies. The VWR
International Group is headquartered in West Chester, Pennsylvania.
For more information on VWR International or a copy of this release,
phone (610) 430-7258 or visit www.vwr.com, or
write, VWR International, Inc., 1310 Goshen Parkway, P.O. Box 2656, West
Chester, PA 19380-0906.
VWR and design are trademarks of VWR International, Inc.
Safe Harbor Statement
Certain statements in this news release that are not historical fact
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Stockholders and other
readers are cautioned not to place undue reliance on these
forward-looking statements. Stratagene generally identifies
forward-looking statements by using words like "believe," "intend,"
"target," "expect," "estimate," "may," "should," "plan," "project,"
"contemplate," "anticipate," "predict" or similar expressions. You can
also identify forward-looking statements by discussions of strategies,
plans or intentions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the
actual results of Stratagene to be materially different from historical
results or from any results expressed or implied by such forward-looking
statements. Among the important factors that could cause actual results
to differ materially from those contained in or implied by the
forward-looking statements are risks associated with the company's
inability to sufficiently anticipate market needs and develop products
and product enhancements that achieve market acceptance, the company's
ability to compete effectively in the diagnostics and life science
research markets, variability of the company's quarterly revenues and
operating results, the failure of the company to retain key employees,
the company's ability to obtain additional debt or equity financing, the
possibility of declining sales due in part to a reduction in research
and development budgets or government funding, the company's ongoing
ability to protect its own intellectual property rights and to avoid
violating the intellectual property rights of third parties, extended
manufacturing difficulties and currency fluctuations. For more
information about these and other factors that could cause actual
results to differ materially from those contained in or implied by the
forward-looking statements please see Item “1A.
Risk Factors" included in Stratagene's Annual Report on Form 10-K for
the year ended December 31, 2005 and in other reports filed by
Stratagene from time to time with the Securities and Exchange
Commission, including Quarterly Reports on Form 10-Q.
Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer
and marketer of specialized life science research and diagnostics
products, announced today that VWR International, Inc. will become a
distributor of Stratagene's full line of research products in Canada.
The companies expect that customers will be able to access Stratagene
products through VWR beginning in October 2006.
Under the terms of the agreement, Stratagene and VWR will service
Canadian customers in an integrated manner. In addition to increasing
Stratagene's presence in the Canadian market with broader sales
representation and customer relationships, VWR will inventory
Stratagene products in warehouses located in Edmonton and Mississauga
to provide Canadian customers with faster and more economical
delivery. Stratagene will continue to support Canadian customers with
direct sales representation and field applications support personnel
in Canada as well as provide technical support and instrument service
from its U.S. offices.
"Both of our companies possess strengths which we want to leverage
to provide the best life science research products and support to our
mutual Canadian customers," said Joseph A. Sorge, MD, President and
CEO of Stratagene. "Stratagene is recognized as a premier brand name
in life sciences and is a leader in many product areas, while VWR
provides well-established, reputable distribution and coverage of the
Canadian market. Together, we believe we offer Canadian customers
unparalleled combination of value."
"This agreement significantly enhances VWR's network of supplier
partnerships by extending Stratagene's industry-leading life science
research products to our customers," said Brian Kerslake, VWR Vice
President of Life Science. "Our relationship will continue to
strengthen VWR's ability to provide our customers with superior
solutions and technology."
About Stratagene Corporation
Stratagene is a developer, manufacturer and marketer of
specialized life science research and diagnostic products. The
Company's life science research unit supports advances in science by
inventing, manufacturing and distributing products that simplify,
accelerate and improve research. These products are used throughout
the academic, industrial and government research sectors in fields
spanning molecular biology, genomics, proteomics, drug discovery and
toxicology. The Company's diagnostic unit develops and manufactures
products for urinalysis as well as high quality automated instrument
and reagent systems that use blood samples to test for more than 1,000
different allergies and autoimmune disorders. In addition, by
combining its expertise in diagnostics and molecular biology, as well
as its experience with FDA regulatory procedures, the Company is
pursuing opportunities to expand its product portfolio to include
molecular diagnostic kits and instrumentation. More information is
available at www.stratagene.com.
About VWR International, Inc.
VWR International is a leader in the global research laboratory
industry with worldwide sales in excess of $3.1 billion US dollars.
VWR's business is highly diversified across a spectrum of products and
services, customer groups and geography. The company offers more than
1,200,000 products, from more than 2,500 manufacturers, to over
250,000 customers throughout North America and Europe. VWR's primary
customers work in the pharmaceutical, life science, chemical,
technology, food processing and consumer product industries. Other
important customers include universities and research institutes;
governmental agencies; environmental testing organizations; and
primary and secondary schools. VWR International affiliates operate in
20 countries and employ approximately 6,100 people. The company's
mission is to deliver excellence in the distribution of scientific
supplies. The VWR International Group is headquartered in West
Chester, Pennsylvania.
For more information on VWR International or a copy of this
release, phone (610) 430-7258 or visit www.vwr.com, or write, VWR
International, Inc., 1310 Goshen Parkway, P.O. Box 2656, West Chester,
PA 19380-0906.
VWR and design are trademarks of VWR International, Inc.
Safe Harbor Statement
Certain statements in this news release that are not historical
fact constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Stockholders and
other readers are cautioned not to place undue reliance on these
forward-looking statements. Stratagene generally identifies
forward-looking statements by using words like "believe," "intend,"
"target," "expect," "estimate," "may," "should," "plan," "project,"
"contemplate," "anticipate," "predict" or similar expressions. You can
also identify forward-looking statements by discussions of strategies,
plans or intentions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the
actual results of Stratagene to be materially different from
historical results or from any results expressed or implied by such
forward-looking statements. Among the important factors that could
cause actual results to differ materially from those contained in or
implied by the forward-looking statements are risks associated with
the company's inability to sufficiently anticipate market needs and
develop products and product enhancements that achieve market
acceptance, the company's ability to compete effectively in the
diagnostics and life science research markets, variability of the
company's quarterly revenues and operating results, the failure of the
company to retain key employees, the company's ability to obtain
additional debt or equity financing, the possibility of declining
sales due in part to a reduction in research and development budgets
or government funding, the company's ongoing ability to protect its
own intellectual property rights and to avoid violating the
intellectual property rights of third parties, extended manufacturing
difficulties and currency fluctuations. For more information about
these and other factors that could cause actual results to differ
materially from those contained in or implied by the forward-looking
statements please see Item "1A. Risk Factors" included in Stratagene's
Annual Report on Form 10-K for the year ended December 31, 2005 and in
other reports filed by Stratagene from time to time with the
Securities and Exchange Commission, including Quarterly Reports on
Form 10-Q.